WASHINGTON — A federal judge in New Jersey on Monday dealt a blow to two drugmakers challenging the Biden administration’s new Medicare drug price negotiation authority, ruling that the program is constitutional.
The challenge, brought by Bristol Myers Squibb and Johnson & Johnson, argued that the drug price program created in the Inflation Reduction Act is an unconstitutional confiscation of their drugs by the government, a violation of their right to freedom of speech, and an unconstitutional condition to participate in the Medicare program.
The loss is a setback for the pharmaceutical industry’s strategy of getting split decisions in lower courts across the country to eventually get the attention of the Supreme Court.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect